Key Takeaways CHWY trades at 0.83x forward sales, well below industry, sector and S&P 500 averages.Chewy grew Autoship to 84% of sales as adjusted EBITDA margins expanded year over year.CHWY guides for a Q4 EPS step-down and possible sequential customer decline.Chewy, Inc. (CHWY) has made meaningful progress on profitability while leaning on a subscription-heavy model that supports steadier demand than most e-commerce categories. The stock looks undervalued, even after rebounding from recent lows. Still, ne ...

Key Takeaways FCN saw a 2.2% uptick in its 2026 earnings estimate with no downward revisions.FTI Consulting beat earnings estimates in the last four quarters, averaging a 26.2% surprise.FCN repurchased 5.3M shares in 2025, boosting ROE to 15.4% amid strong cash and no current debt.FTI Consulting, Inc. (FCN) is a global expert firm for organizations tackling crises and transformation. Let us delve deeper to find out why this stock is a must-have for investors.What Makes FCN an Attractive Pick?Solid Rank: FCN ...

Netflix co-CEO Ted Sarandos said Sunday he knew "right away" he would decline to counter Paramount’s winning attempt to buy Warner Bros. Discovery, admitting rival chief executive David Ellison made a superior offer.  Netflix dropped its bid to buy Warner Bros. Discovery on Thursday after the company announced Paramount's latest bid to buy all of its assets, including CNN, was "superior.""We had a very tight range that we’d be willing to pay and made that offer back when we closed this deal. We hadn’t moved ...

RT Kaizen D. Asiedu (@thatsKAIZEN)Please don’t use ChatGPT https://t.co/65EBvKyDNV ...

You can find original article here WealthManagement. Subscribe to our free daily WealthManagement newsletters. A New York-based broker has pleaded guilty to defrauding clients he initially lured from his time as a rep for Merrill Lynch and Pinnacle Investments, according to the Justice Department. In New York federal court last week, Dean Dellas pleaded guilty to wire fraud and aggravated identity theft in connection with a scheme that stole about $686,000 from clients. Dellas is based in Cazenovia, N.Y., ...

Bed Bugs: Ways To Avoid Them, Deal With Them When Traveling https://t.co/cGH36HUQvtPhoto: Miguel Medina/AFP via Getty Images https://t.co/XcGwyVP7bm ...

Summary of XOMA Corporation FY Conference Call Company Overview - **Company Name**: XOMA Corporation (NasdaqGM:XOMA) - **Enterprise Value**: Approximately $550 million - **Market Capitalization**: Around $450 million - **Cash on Balance Sheet**: About $80 million - **Outstanding Loan**: One loan with Blue Owl for VABYSMO - **Preferred Shares**: Approximately $65 million - **Phase III Assets**: Highest number of Phase III assets in development, totaling about 15 [12][14] Core Strengths and Challenges - **Strengths**: - Largest portfolio of any royalty company with over 120 assets - Profitable products across the portfolio, unlike many biotech companies that are not profitable at launch [12][13] - Unique investment strategy covering the entire drug development spectrum from preclinical to commercial assets [13] - **Challenges**: - Operating with a limited capital situation compared to competitors [21] - Need to manage binary risks associated with biotech investments [14] Portfolio Development Strategy - **Portfolio Building**: - Transitioned from 1 commercial asset to 7 since 2023, focusing on a balanced approach between late-stage and early-stage assets [15] - Emphasis on acquiring undervalued assets in overlooked therapeutic areas [15][16] - **Wind Down Transactions**: - Engaged in transactions where companies pay XOMA cash to acquire assets, generating approximately $12 million in net capital last year [19] - Accumulated about $500 million in tax deductions through these transactions, shielding future profits from federal taxes [20][22] Upcoming Milestones and Catalysts - **Phase III Programs**: - 15 Phase III programs expected to read out over the next 24-30 months, with significant news flow anticipated [29] - Recent Phase III results for Rezolute and Gossamer were unfavorable, but confidence remains in upcoming trials [30][31] - **Regulatory Decisions**: - Anticipated regulatory decisions for MIPLYFFA and Ojenda, with positive developments for ONIVYDE expected to enhance royalty growth [44][46] Market Potential and Product Insights - **Rezolute**: - Market size for tumor hyperinsulinism expected to be significantly larger than congenital hyperinsulinism, with potential revenues exceeding $500 million [50][59] - **MIPLYFFA Launch**: - Exceeded expectations due to rapid patient identification and weight-based dosing advantages [66][70] - **Ovaprene**: - Positioned in the growing non-hormonal market, with expectations for significant market potential as it approaches Phase III trials [78][80] Financial Strategy and Capital Allocation - **Capital Allocation**: - Focus on accumulating assets without significant cash outlays while buying back stock to enhance future returns [88][89] - Interest in acquiring larger biotech companies to access undervalued royalties [91] - **Profitability Outlook**: - Projected profitability by 2027 driven by royalties from MIPLYFFA and Ojenda, alongside VABYSMO [86][87] Conclusion - XOMA Corporation is strategically positioned with a robust portfolio and a focus on risk management and capital efficiency. The company aims to leverage its unique asset base and upcoming milestones to drive shareholder value and achieve profitability in the coming years.

It has been a rough year for nuclear energy stocks that aim to bring small modular reactors into the mainstream. Oklo (NYSE: OKLO), for example, has seen its shares fall by more than 10% so far this year. NuScale Power (NYSE: SMR), meanwhile, is down by nearly 20%. But the story of small modular reactors (SMRs) -- a technology that could revolutionize nuclear power by making it faster, cheaper, and more efficient to deploy nuclear infrastructure -- won't be measured over a period of months. This story won ...

“Our relationship with the United States will never be the same as it was, even though, in the new protectionist world, we have the best trade deal of any country,” he explained.Simply put, the good old days are gone — and won’t return.“The jobs of workers in our industries most affected by U.S. tariffs — autos, steel, lumber — are under threat,” Carney said in October (1), adding that uncertainty is causing Canadian businesses to hold back investments.Carney also cautioned that many of Canada’s former stre ...

PROCEPT BioRobotics (NasdaqGM:PRCT) FY Conference March 02, 2026 11:50 AM ET Speaker0Devices research team, we are in the last session of the first morning of the 46th annual TD Cowen Healthcare Conference. We are fortunate to have executives from PROCEPT BioRobotics, CEO Reza Zadno to my right, your left, and CFO Kevin Waters. Gentlemen, thanks for joining us today. It was a busy week last week for you guys. You had earnings, you had Investor Day, you guys laid out a lot of intel on fourth quarter dynamics ...